Charles River Laboratories International (CRL) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Charles River Laboratories International, Inc. (CRL) insider buying and selling: 2 purchases, 12 sales
97 Form 4 Table I transactions filed with the SEC by Charles River Laboratories International, Inc. insiders between 2025-11-07 and 2026-10-07 (15-month history): 2 open-market purchases and 12 sales, plus 83 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $16.9M by Foster James C on 2026-06-29.
Charles River Laboratories International insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Charles River Laboratories International insiders filed 2 purchases worth $7k and 11 sales worth $42.9M on the open market. The net balance is on the sell side: $42.9M more sold than bought.
The biggest buyer was Laplume Joseph W (EVP, Corp Strategy & Develop): $4k in 1 purchase, out of 2 different buyers. The biggest seller was Foster James C (Director): $34.8M in 3 sales, out of 6 different sellers.
The largest trade of the period was a sale of $16.9M on Jun 29, 2026, by Foster James C (Director), under a 10b5-1 plan. Form 4 on sec.gov (0001100682-26-000111).
Of the 11 sales, 8 (73%, $39.9M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 3 do not.
The last three months show 1 purchase and 10 sales, against 0 and 1 in the three before. The latest purchase is from Sep 30, 2026; the latest sale from Oct 5, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Charles River Laboratories International has more sales than 35 of the other 58, ranks 18 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Charles River Laboratories International included.
The 20 most important trades
The 2 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 97 CRL trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-03-03 | 2026-03-04 | Laplume Joseph W | EVP, Corp Strategy & Develop | $4k | P — Open-market purchase | SEC |
| 2026-09-30 | 2026-10-02 | Coleman Glenn | EVP & Chief Financial Officer | $3k | P — Open-market purchaseForm 4 footnoteF1 The shares were acquired pursuant to the Company's Employee Stock Purchase Plan at the fair market value of the Company's common stock on the purchase date. The Reporting Person elected to participate in the Plan during an open trading window prior to the commencement of the quarterly purchase period. | SEC |
| 2026-06-29 | 2026-07-01 | Foster James C | Director | $16.9M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was adopted by the reporting person on March 6, 2026. | SEC |
| 2026-08-25 | 2026-08-27 | Foster James C | Director | $10.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. | SEC |
| 2026-08-10 | 2026-08-11 | Foster James C | Director | $7.9M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. | SEC |
| 2026-08-11 | 2026-08-13 | Girshick Birgit | Chief Executive Officer | $1.8M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025. | SEC |
| 2026-08-06 | 2026-08-10 | Knell Michael Gunnar | SVP, Finance and CAO | $1.7M | S — Open-market sale6 Form 4 footnotesF1 This transaction was executed in multiple trades at prices ranging from $258.77 to $259.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $259.97 to $260.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $261.00 to $261.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $262.26 to $262.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $263.39 to $264.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $264.91 to $265.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-08-05 | 2026-08-06 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | $1.3M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026. | SEC |
| 2026-08-06 | 2026-08-10 | Creamer Victoria L | EVP & Chief People Officer | $1.1M | S — Open-market sale | SEC |
| 2026-08-11 | 2026-08-13 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | $1.0M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026. | SEC |
| 2026-08-19 | 2026-08-20 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | $600k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026. | SEC |
| 2026-10-05 | 2026-10-07 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | $303k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was adopted on March 4, 2026. | SEC |
| 2026-08-18 | 2026-08-20 | Andrews Nancy C | Director | $163k | S — Open-market sale | SEC |
| 2025-08-22 | 2026-01-20 | Laplume Joseph W | EVP, Corp Strategy & Develop | $65k | S — Open-market sale | SEC |
| 2026-08-25 | 2026-08-27 | Foster James C | Director | $6.7M | M — Option exercise (scheduled 10b5-1) | SEC |
| 2026-08-10 | 2026-08-11 | Foster James C | Director | $5.2M | M — Option exercise (scheduled 10b5-1) | SEC |
| 2026-05-01 | 2026-05-04 | Coleman Glenn | EVP & Chief Financial Officer | $3.5M | A — Grant or awardForm 4 footnoteF1 Unvested restricted stock units annually ratably vest on: May 1, 2027; May 1, 2028; May 1, 2029; and May 1, 2030. | SEC |
| 2026-01-30 | 2026-02-02 | Foster James C | Chairman, President and CEO | $3.1M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-03-02 | 2026-03-04 | Foster James C | Chairman, President and CEO | $3.0M | A — Grant or award2 Form 4 footnotesF1 100% of the unvested restricted stock units vest on March 2, 2028. F2 Reflects the exempt transfer pursuant to Rule 16a-13 of 9,220 shares from the 2025 GRAT account to direct holdings. | SEC |
| 2026-05-29 | 2026-06-02 | Girshick Birgit | Chief Executive Officer | $1.8M | A — Grant or awardForm 4 footnoteF1 Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Nov 7, 2025 and Oct 7, 2026, Charles River Laboratories International, Inc. open-market activity adds up to 2 purchases worth $7k and 12 sales worth $43.0M. The net balance is $43.0M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Charles River Laboratories International, Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 32 | $6.3M |
| A | Grant or award | 29 | $16.8M |
| G | Gift | 13 | $0 |
| S | Open-market sale | 12 | $43.0M |
| M | Option exercise | 9 | $15.6M |
| P | Open-market purchase | 2 | $7k |
| Total | Everything filed in the period | 97 | $81.7M |
20 of the 97 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 18 distinct people or entities have filed Charles River Laboratories International, Inc. transactions: 2 bought on the open market and 7 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 7 who sold on the open market (12 sales in all), the three biggest sellers account for $39.9M of the $43.0M: 93% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Foster James C | Director | 12 | — | $34.8M (3) | 2026-08-27 |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | 18 | — | $3.3M (4) | 2026-10-07 |
| Girshick Birgit | Chief Executive Officer | 13 | — | $1.8M (1) | 2026-08-20 |
| Knell Michael Gunnar | SVP, Finance and CAO | 10 | — | $1.7M (1) | 2026-08-10 |
| Creamer Victoria L | EVP & Chief People Officer | 9 | — | $1.1M (1) | 2026-08-10 |
| Andrews Nancy C | Director | 5 | — | $163k (1) | 2026-08-20 |
| Laplume Joseph W | EVP, Corp Strategy & Develop | 10 | $4k (1) | $65k (1) | 2026-08-11 |
| Coleman Glenn | EVP & Chief Financial Officer | 3 | $3k (1) | — | 2026-10-02 |
Shown here are the 8 who moved the most money, out of 18. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2026: 0 purchases and 9 sales, worth $25.7M. 9 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $65k |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 1 | $4k | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 1 | $16.9M |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 9 | $25.7M |
| Sep 2026 | 1 | $3k | 0 | $0 |
| Oct 2026 | 0 | $0 | 1 | $303k |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Charles River Laboratories International, Inc. (CRL) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
8 of the 12 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Charles River Laboratories International's 2 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 7, 2026, and a Form 4 arrives up to two business days after the trade.
13 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.